75MO Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): Results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6.

MLA

Wainberg, Z. A., et al. “75MO Health-Related Quality of Life (HRQoL) in FGFR2b-Overexpressing, Advanced Gastric or Gastroesophageal Junction Cancer (G/GEJC): Results from the FIGHT Trial Comparing Bemarituzumab (BEMA) + Modified FOLFOX6 (MFOLFOX6) to Placebo (PBO) + MFOLFOX6.” Annals of Oncology, vol. 33, Nov. 2022, pp. S1460–61. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.10.111.

APA

Wainberg, Z. A., Enzinger, P. C., Qin, S., Yamaguchi, K., Gnanasakthy, A., Taylor, K., Jamotte, A., Majer, I., & Kang, Y.-K. (2022). 75MO Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): Results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6. Annals of Oncology, 33, S1460–S1461. https://doi.org/10.1016/j.annonc.2022.10.111

Chicago

Wainberg, Z.A., P.C. Enzinger, S. Qin, K. Yamaguchi, A. Gnanasakthy, K. Taylor, A. Jamotte, I. Majer, and Y-K. Kang. 2022. “75MO Health-Related Quality of Life (HRQoL) in FGFR2b-Overexpressing, Advanced Gastric or Gastroesophageal Junction Cancer (G/GEJC): Results from the FIGHT Trial Comparing Bemarituzumab (BEMA) + Modified FOLFOX6 (MFOLFOX6) to Placebo (PBO) + MFOLFOX6.” Annals of Oncology 33 (November): S1460–61. doi:10.1016/j.annonc.2022.10.111.